|
|
United States Type 2 Diabetes MarketPublished by: Intellent Published: Nov. 14, 2009 - 78 Pages Table of Contents
AbstractIntellent's new industry report focuses on the US type 2 diabetes market. This report provides valuable insight and access to the competitive information and analysis necessary to make decisions regarding the direction of the market from 2009 -2013. This primary research report features information and analysis that can't be found anywhere else. Our report features information gathered from pharmaceutical, payer, and key opinion leader interviews. This report reveals what changes lay ahead for the diabetes market in the US. It evaluates current drugs and makes projections on drugs poised to influence the future market.Diabetes is one of the most common diseases in the United States, affecting more than 24 million people. It is a metabolic disorder mainly caused by a defect in insulin production or absorption, resulting in a high level of blood glucose or blood sugar. A person having blood glucose level HbA1c of greater than seven is considered to be diabetic. It is estimated that approximately 90 to 95 percent of diabetics are type 2 diabetics and can be treated by oral anti-diabetics or with a combination of injectable insulin and anti-diabetic drugs. In 2008, the US anti-diabetic market was estimated to be worth $11.5 billion. The market is forecasted to grow at a cumulative annual growth rate (CAGR) of 6.4 percent over the forecast period. By the end of the forecast period, 2013, the market is estimated to generate $15.7 billion in revenues. Our Intellent diabetes report provides detailed analyses into the potential growth in revenue from the new DPP-IVs and GLP-1s. The report also delivers information on which segments are poised to grow the most over our forecast period as some of the biggest selling drugs lose patent protection. We provide exclusive payer opinions on how effective the current anti-diabetic armamentarium is and what managed care sees as keys to the future. Intellent utilizes our deep expertise in the field of diabetes to provide an accurate and detailed SWOT analysis of some of the most promising agents about to come to market, such as liraglutide, exenatide LAR, saxagliptin, dapagliflozin, and many more. Intellent also provides detailed pipeline analysis about which companies are developing the most anti-diabetics and where they are in development. Our report breaks down the therapeutic area as a whole, in order to show readers which companies are the most heavily invested. Intellent also provides an up-to the minute picture of both early and late phase drugs. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||